Belantamab combinations for relapsed multiple myeloma
Treatments studied
This study looks at how well a treatment combining belantamab with other drugs works for patients whose multiple myeloma has come back. It may be an option if you have already received this drug combination on a compassionate use basis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has returned or stopped responding to treatment.
- You have already received at least one dose of a belantamab combination (with bortezomib or pomalidomide) under compassionate use.
- You were 18 or older when you started that belantamab combination.
- You received the belantamab combination for your first or second relapse, not later.
- You have not received a belantamab combination for a fourth or later relapse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This trial tests a combination of two drugs, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination works better than using one drug alone.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This Phase 2 study tests belantamab mafodotin in people with multiple myeloma that has come back or is not responding to several prior treatments. It may help shrink the cancer and improve disease control when standard options have already been tried.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Hear when a new Relapse Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.